Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months
Crossref DOI link: https://doi.org/10.1007/s10545-017-0123-6
Published Online: 2018-01-05
Published Print: 2018-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wasserstein, Melissa P.
Diaz, George A.
Lachmann, Robin H.
Jouvin, Marie‐Hélène
Nandy, Indrani
Ji, Allena J.
Puga, Ana Cristina
Version of Record valid from 2018-01-05
Text and Data Mining valid from 2018-01-05